Wall Street’s Hottest Stock Has a Waiting List. Here’s How to Skip It.

A note from our friends at The Oxford Club(ad)

From the man who tabbed NVIDIA before it soared 6,271%
over 7 years at its peak
Wall Street’s Hottest Stock Has a Waiting List. Here’s How to Skip It.

Wealthy investors are lining up for Anthropic shares and coming up empty. Tech Visionary, Matt McCall, says you can get into a backdoor opportunity today for less than $100 a share.

Anthropic, the company behind Claude, is set to go public at a record $2 trillion valuation.

It could top SpaceX as the biggest IPO in history.

And right now, almost nobody can buy a single share.

One Wall Street broker, whose firm trades about 1,000 private stocks, told TechCrunch:

“The hardest stock to source in our marketplace is Anthropic. There’s just no sellers.”

Even Goldman Sachs is charging clients 15% to 20% of their profits just for a way in.

The Line Is Out the Door

Meanwhile, people who already own a piece of Anthropic are holding on tight.

While everyone else is stuck in line. Even wealthy investors are struggling to get shares.

And it’s all leading to the most anticipated IPO in history.

When Anthropic finally goes public, millions of regular folks will rush to buy whatever they can get.

But tech legend Matt McCall isn’t getting in line.

“Most people are going to wait for Anthropic to go public and then buy as many shares as possible,” he says. “But I think that’s a huge mistake.”

Who Is Matt McCall?

There is a short list of analysts in America who were early on the AI boom.

Matt McCall is one of them.

He’s the Head Innovation Strategist at Monument Traders Alliance and editor of The McCall Innovation Report.

Over the past two decades, McCall has written about 50 stocks that went on to peak gains of 1,000% or more. Including:

  • Tesla, before it climbed as high as 3,129%
  • NVIDIA, before it soared a peak 6,271% in 7 years
  • AMD, which he singled out in 2009

That’s why people call him “Mr. 1,000%.”

On March 6, 2009, McCall went on FOX Business and gave away nine stocks. One was AMD, trading around two dollars. By 2026 it rose 25,000%, enough to turn a $5,000 stake into more than $1.28 million.

No Waiting List Required

McCall’s play isn’t Anthropic. It’s a stock linked to Anthropic that you can buy right now in a regular brokerage account.

No waiting list. No special broker. No fighting Wall Street for scraps.

He calls it a “Second IPO.”

It may sound too good to be true. But it has happened before.

When Rivian went public in 2021, Ford owned a 12% stake. In the six months around Rivian’s IPO, Ford shares roughly doubled.

Yahoo quietly built a huge stake in Alibaba. In the two years around Alibaba’s IPO, Yahoo shares could have tripled your money.

It happened again shortly after EchoStar acquired $8.5 billion in SpaceX shares. In the months leading up to the SpaceX IPO, its shares soared 600%.

Now it’s happening again!

Anthropic’s “Silent Partner”

Years before the IPO frenzy, a much smaller firm took a $100 million stake in Anthropic. It beat Apple, NVIDIA, Amazon and Google to the punch.

Today, the entire company is valued at less than $15 billion. That’s 100x smaller than Anthropic.

McCall believes its early stake could cause it to double or triple in the years ahead.

And you can buy it for less than $100 a share.

We sat McCall down in front of our cameras to get the whole story. He even gave away the name and ticker.

For the time being, you can watch it free.

WATCH THE FREE INTERVIEW (NAME AND TICKER INSIDE)

“If history repeats… investors could double or triple their money in the years ahead.” – Matt McCall

 
 
 
Bonus Article

AstraZeneca Cut 600 Sales Jobs. Green Flag or Warning?

When a company fires 600 people selling two of its branded drugs, you can frame it two ways. AstraZeneca wants you to pick the optimistic one.

On November 13, Bloomberg reported that AstraZeneca had cut about 600 positions from its US respiratory and immunology commercial teams as part of a three-year cost-savings programme the company unveiled in October. AstraZeneca has said the programme would incur up to $2 billion in one-time restructuring costs and deliver $1.5 billion in annualised pre-tax run-rate benefits, with savings largely reinvested into the pipeline. Bloomberg also reported AstraZeneca pulled back its partnership with contract sales organization Syneos Health in the US. Management’s line is consistent: this is a reallocation, not a retreat. The savings go into the pipeline. The story gets better from here.

But the numbers underneath that framing deserve a harder look.

What the Drug Sales Actually Say

After an FDA label expansion in April to include maintenance treatment of asthma, Breztri’s US sales in the third quarter increased only 2% year over year to $170 million. That is a thin return on a significant regulatory win. Airsupra performed worse, with $42 million in US sales in Q3, down 3% year over year. So the two drugs that just lost their dedicated sales force were already losing momentum before the cuts arrived.

By scaling back commercial headcount in a competitive respiratory and immunology landscape dominated by rivals like GSK’s Trelegy and Sanofi and Regeneron’s Dupixent, AstraZeneca is wagering that incremental R&D investment will yield superior shareholder returns compared to additional marketing spend. That is a defensible bet in theory. The problem is the competitive dynamics make it a risky one in practice.

Dupixent generated net sales of €9.324 billion in the first half of 2026, up 27.5% year over year on a reported basis. GSK’s Specialty Medicines segment posted 14% growth at constant exchange rates in the first half of 2026. Both rivals are leaning in. AstraZeneca is stepping back.

The Cleaner Story Argument

There is a legitimate case for AZN shares here, and it does not really rest on Breztri or Airsupra. Breztri still grew 16% at constant exchange rates to $1.073 billion across the first nine months of 2026, showing global traction even as the US slows. The bigger argument is that management is making a deliberate choice to stop throwing money at a maturing franchise and redirect it toward what actually moves the stock.

AstraZeneca has pointed to a deep late-stage slate, and in its Q3 update CEO Pascal Soriot said the company had reported 12 positive Phase III programme readouts with a collective peak-year revenue potential well in excess of $10 billion. At constant currencies, AstraZeneca said total revenue grew 7% year on year in Q3 and core EPS rose 14%, while reiterating full-year guidance and describing the three-year cost programme as a way to redeploy resources and fund the pipeline.

The pipeline-versus-commercial tension is not unique to AstraZeneca. Novartis showed how a pharma company can raise its profit outlook even when a key pipeline drug disappoints.

RBC Capital raised its price target on AstraZeneca shares to GBP 152.50 from GBP 145.00 while maintaining an Outperform rating. Nordea moved AstraZeneca from Sell to Buy and lifted its target to SEK 1,900, saying it expects investor attention to shift toward the cardiovascular pipeline.

What Could Go Wrong

Cutting sales staff is one thing. Winning back lost ground in respiratory is harder. Bloomberg’s reporting suggested the moves may not be the company’s last, which means the restructuring has further to run and execution risk compounds with each round. Meanwhile, Dupixent is not standing still. Its maker keeps stacking new indications while AZN is thinning out the team selling into the same disease categories.

Valuation views remain divided because pipeline growth must offset patent expiries, pricing pressure, and clinical risks. At roughly 17 times forward earnings, the stock prices in a lot of pipeline success that still needs to arrive.

The Bottom Line

AstraZeneca is making a coherent argument: Breztri and Airsupra do not need 600 more salespeople, they need better drugs behind them. If the pipeline delivers, this restructuring looks like discipline. If late-stage programs disappoint, cutting the commercial team that was at least generating some revenue will look like the wrong trade. For buyers today, AZN is a pipeline bet dressed up as a cost story. That is worth owning with clear eyes, not confusion about what changed.

More From Author

Circle March 19 on your calendar

One BDC Worth Buying While the Sector Sells Off

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.